This circuit has been shown in breast cancer (METTL3→IGF2BP3), bladder cancer (JNK–METTL3→IGF2BP1), and intrahepatic cholangiocarcinoma (where ALKBH5 demethylation maintains PD-L1), with mechanistic interventions reversing immune evasion phenotypes and, in some settings, sensitizing tumors to anti-PD-1 therapy. Here, CD274 is linked to breast cancer.